Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirapazamine Embolization vs TACE for Intermediate-stage HCC
NCT06848556Phase 2Terminated
- Sponsor
- Raygene
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirapazamine in hepatocellular carcinoma (HCC) (5 arms), sponsored by Raygene. Primary endpoints: Peak Plasma Concentration at 24 hours, Area under the plasma concentration versus time curve at 24 hours and 3 more. Started May 2021; status: terminated.
02
Drugs
tirapazamine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06848556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848556.